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Volume 52, Number 3 Abstracts 803and CLI on presentation (P  .002). Age 50 was also an independent
predictor of limb loss compared with age 60 (P  .05).
Conclusion: Endovascular options are commonly being used in young
patients, especially claudicants, but patency rates and outcomes remain very
poor.
Demographic and clinical characteristics by age group
Characteristics 50 years 51-60 years 60 years P
Patient level (n  97) (n  103) (n  98)
Mean SD Mean SD Mean SD
Age at surgery, mean
 SD, y
45  5 56  3 73  8 .001
% (No.) % (No.) % (No.)
Male 57 (55) 65 (67) 63 (62) .44
History
CAD 43 (42) 55 (57) 62 (60) .03
ESRD 6 (6) 19 (20) 13 (13) .02
Hypertension 76 (74) 82 (84) 87 (85) .17
Hypercholesterolemia 58 (56) 64 (66) 69 (60) .28
Diabetes 38 (37) 43 (44) 62 (61) .002
Smoking 83 (80) 79 (81) 62 (61) .003
Hypercoagulable state 16 (15) 5 (5) 3 (2) .004
Limb level (n  139) (n  151) (n  119)
Procedure
Percutaneous 40 (55) 52 (78) 52 (61) .15
Open surgery 57 (79) 46 (69) 47 (57) .15
Hybrid 3 (5) 2 (4) 1 (1) .15
Indication
Claudication 46 (64) 45 (68) 37 (42) .16
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Objectives: Catheter-directed intra-arterial thrombolysis for acute
peripheral arterial ischemia has become a standard practice for acute
arterial thrombosis. There has been significant amount of literature
published as far as the choice of the thrombolytic agent and injection
techniques. One technique used to accelerate thrombolysis is with the
use of ultrasound imaging (EKOS). We looked at our experience to
compare the outcomes with a simple side-hole infusion catheter (Uni-
fuse) vs EKOS catheters.
Methods: We retrospectively reviewed our data set from January
2006 to August 2008 for all the patients undergoing catheter-directed
thrombolysis for acute lower extremity arterial ischemia. The primary
comparison variables were the duration of thrombolysis and technical
success rate. The technical success rate was defined as complete or nearly
complete clearance of clot burden allowing intervention in form of
percutaneous transluminal angioplasty (PTA) and/or stenting. The data
were also stratified according to the location of the thrombus, complica-
tions, mortality, and limb loss rates. Tissue plasminogen activator (TPA)
was infused at 0.5 to 2.0 mg/h and patients underwent serial angiogra-
phy every 12 to 24 hours.
Results:There were 69 cases of peripheral catheter-directed thrombol-
ysis with the Unifuse catheter and 22 were performed using the EKOS
catheter during the study period. The average duration of thrombolysis was
1.65 days (SD, 0.83) in the Unifuse catheter group vs 1.9 days (SD, 0.92) in
the EKOS catheter group (P  .22). Technical success was achieved in 72%
in the Unifuse group vs in 86% in the EKOS group (P  .31). Ten of 69
(14%) in Unifuse group and 2 of 22 (9%) in the EKOS group had limb loss
(P  .46). Complications were compartment syndrome requiring fas-
ciotomy and bleeding requiring premature cessation of thrombolysis. No
deaths occurred as an immediate result of complications. The complication
rate was 13% in the Unifuse group vs 10% in the EKOS group (P  .46).
Conclusions: There was no statistically significant difference in the
outcomes in catheter-directed thrombolysis in the treatment of acute
arterial ischemia using the Unifuse catheter vs the more expensive EKOS
catheter.
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Objectives: In-stent restenosis is the primary failure mode of endo-
vascular treatment of occlusive disease in the femoropopliteal segment.
Cryoplasty has been proposed to reduce intimal hyperplasia through
induction of apoptosis. We sought to evaluate the efficacy of cryoplasty
for treatment of in-stent restenosis compared with conventional balloon
angioplasty (CBA).
Methods: After IRB approval, a retrospective record review was per-
formed of reinterventions for in-stent restenosis by a single vascular surgery
group at a university hospital. Reinterventions involving cryoplasty and CBA
were evaluated at 1, 3, 6, and 12 months after intervention with duplex
imaging to identify significant recurrent stenosis utilizing established veloc-
ity criteria. Data collected included basic demographic information and
comorbidities as well as time to restenosis. Statistical analysis was performed
using Kaplan-Meier survival curves with the log rank test, Wilcoxon rank
test, and Cox proportional hazards models.
Results: FromDecember 2004 toNovember 2009, 76 reinterventions
were performed using CBA (n  39) or cryoplasty (n  37) for in-stent
restenosis without placement of additional stents. Periprocedural technical
success (30% residual stenosis) was 100% for both groups, with no com-
plications. The two cohorts were statistically similar in mean age, gender
distribution, comorbidities (including active tobacco use), and use of statins,
aspirin, and Plavix. However, the mean lesion length was significantly
longer in the cryoplasty cohort (CBA: 140.9 mm, Cryo: 191.7 mm; P 
.032). The mean time to recurrent stenosis or need for additional
secondary intervention was significantly shorter for the cryoplasty cohort
than for the CBA, 4.09 and 10.79 months, respectively (P  .0001).
Recurrent stenosis-free survival was significantly lower in the cryoplasty
cohort at 3 months (CBA: 96.9%, Cryo: 88.9%) and 6 months (CBA:
84.0%, Cryo: 43.8%; P  .0089).Conclusions: Cryoplasty as a modality for treatment of in-stent steno-
sis in the femoropopliteal segment offers no benefit over CBA.
